Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?

@article{Franceschi2016AdjuvantCI,
  title={Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?},
  author={Enrico Franceschi and Marco Bartolotti and Alexandro Paccapelo and Gianluca Marucci and Raffaele Agati and Lorenzo Volpin and Dario Danieli and Claudio Ghimenton and Marina Paolo Gardiman and Carmelo Sturiale and Rosalba Poggi and Maurizio Mascarin and Damiano Balestrini and Barbara Masotto and Alba A Brandes},
  journal={Journal of Neuro-Oncology},
  year={2016},
  volume={128},
  pages={235-240}
}
The standard treatment in children with average-risk medulloblastoma (MB) is reduced-dose radiotherapy (RT) followed by chemotherapy. However, in adults, there is no agreement on the use of adjuvant chemotherapy. We performed a retrospective analysis of adult MB patients with average-risk disease, defined as no postsurgical residual (or ≤1.5 cm2) and no metastatic disease (M0). Main inclusion criteria were: age >16 years, post-surgical treatment with craniospinal irradiation with or without… CONTINUE READING